Evidence map›Paper›PMID 30819278›Full record

ReviewAllergy and asthma proceedings2019

Pathophysiology of atopic dermatitis: Clinical implications.

Jihyun Kim, Byung Eui Kim, Donald Y M Leung

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergy and asthma proceedings, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05719649 (The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial), which is not on this map. Cited by 310 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
310citing papers in PubMed, 13 pooled it
40.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05719649 naunknown statusnot on this mapstarted 2023, after this paper: background citation

The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis - A Double-blind, Multi-center Randomized, Placebo-controlled Clinical Trial

TypeinterventionalSponsorSunWay Biotech Co., LTD.Ran2023 to 2023Enrolled72ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsLactic acid bacteria NTU 101, Placebo
3 · Its place in the literature

Who cites it

310 citing papers in PubMed, 13 syntheses or guidelines pooled it, 591 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Gene variants associated with skin barrier dysfunction in atopic dermatitis: a systematic review and meta-analysis.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. The Effects ofMedicina (Kaunas, Lithuania) · 2023
    Trial
  20. Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.Current therapeutic research, clinical and experimental · 2026
    Review

250 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Jihyun KimFrom the Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Byung Eui KimDepartment of Pediatrics, National Jewish Health, Denver, Colorado.
Donald Y M LeungDepartment of Pediatrics, National Jewish Health, Denver, Colorado.
National Jewish Health · USSungkyunkwan University · KRUniversity of Colorado Denver · US

Funding

THE ROLE OF BACTERIAL TOXINS IN HUMAN SKIN DISEASER01AR041256 · NIAMS · NATIONAL JEWISH HEALTH · PI GOLEVA, ELENA, LEUNG, DONALD YM · 1992 to 2020
$5.9M
NIAMS NIH HHS R01 AR041256
6 · The paper itself

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Genetic predisposition, epidermal barrier disruption, and dysregulation of the immune system are some of the critical components of AD. An impaired skin barrier may be the initial step in the development of the atopic march as well as AD, which leads to further skin inflammation and allergic sensitization. Type 2 cytokines as well as interleukin 17 and interleukin 22 contribute to skin barrier dysfunction and the development of AD. New insights into the pathophysiology of AD have focused on epidermal lipid profiles, neuroimmune interactions, and microbial dysbiosis. Newer therapeutic strategies focus on improving skin barrier function and targeting polarized immune pathways found in AD. Further understanding of AD pathophysiology will allow us to achieve a more precision medicine approach to the prevention and the treatment of AD.

Indexed as

Dermatitis, AtopicHumansInflammationSkin

Identifiers

PMID30819278
PMCPMC6399565
OpenAlexW2920206917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.